

PATENTS ATTY. DOCKET NO. 18377-0059

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	application of:)		
	Brian G. Condie, et al.	.) · ·		
)	Art Unit:	Not Yet Assigned
Serial 1	No.: 10/529,115)		
)	Examiner:	Not Yet Assigned
Filed:	March 24, 2005)		_
)		
For:	Compositions and Methods for)		
	Enrichment of Neural Stem Cells)		•
	Using Ceramide Analogs)	•	

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The citation of information on the attached three pages Form PTO-1449, "List of Information Disclosed by Applicant" is made pursuant to 37 C.F.R. §§ 1.97 and 1.98. A copy of the listed items are enclosed.

Pursuant to the Office's waiver of the requirement under 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national phase patent applications filed after June 30, 2003, no copy of any cited U.S. patent or U.S. patent application publication is being provided herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on June 2, 2005.

Elizabeth Cary Miller - Reg. Nd. 54,708

AO 1318011.1

U.S.S.N.: 10/529,115

Filed: March 24, 2005

INFORMATION DISCLOSURE STATEMENT

As this Information Disclosure Statement is being submitted prior to the issuance of a first office action, no fees are believed to be due.

The citation of this information does not constitute an admission that any of the materials are available as a reference or of priority, or a waiver of any right applicant may have under applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,

Elizabeth Cary Mille

Reg. No. 54,708

Date: June 2, 2005

SUTHERLAND ASBILL & BRENNAN LLP

999 Peachtree Street, NE Atlanta, Georgia 30309-3996 Telephone: (404) 853-8000

Facsimile: (404) 853-8806

10: 0 6 2005 B

Sheet

PTO/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Pates
Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Panents of information unless it contains a valid OMB control number.

18377-0059

Officer the Paperwo 2000001 Act of 1995, no	ersons are required to respond to a c	Discussificial of this interest the contains a valid Own Control Humber.		
TADEMAN 1449/PTO	Complete if Known			
	Application Number	10/529,115		
INFORMATION DISCLOSURE	Filing Date	March 24, 2005		
STATEMENT BY APPLICANT	First Named Inventor	Brian G. Condie		
(Use as many sheets as necessary)	Art Unit			
(Use as many sneets as necessary)	Examiner Name			

Attorney Docket Number

Examiner		•		CUMENTS	
Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documen	Pages, Columns, Lin Where Relevant Passages or Releva Figures Appear
	1	US-5,453,357	09-26-1995	Hogan	
		US-5,589,376	12-31-1996	Anderson et al.	
		US-5,753,506	05-19-1998	Johe	
		US-5,766,948	06-16-1998	Gage et al.	
		US-5,843,780	12-01-1998	Thomson	
		US-5,851,832	12-22-1998	Weiss et al.	
		US-5,958,767	09-28-1999	Snyder et al.	
		US-5,968,829	10-19-1999	Carpenter	
		US-6,200,806 B1	03-13-2001	Thomson	
		US-6,245,566 B1	06-12-2001	Gearhart et al.	
		US-6,410,597 B1	06-25-2002	Bieberich et al.	
		US-6,562,619 B1	05-13-2003	Gearhart et al.	
		FC	REIGN PATENT D	OCUMENTS	
Examiner	Cite No.1	Patent Document Number	Publication Date	Name of Patentee or	Pages, Columns,
Initials*		Country Code ³⁻ Number ⁴⁻ Kind Code ^{2 (if known)}	MM-DD-YYYY	Applicant of Cited Document	Lines, Where Relevant Passages Or Relevant Figures Appear
	1				i igai co rippoui
		WO 98/43679	10-08-1998	The Johns Hopkins University School of Medicine	r igares / ppear
		WO 98/43679 WO 99/53021	10-08-1998 10-21-1999		r igures / ppeu
				School of Medicine	- Igaiso / ppedi
				School of Medicine BresaGen Limited	, igaiso , appear
				School of Medicine	, igaiso appeal
				School of Medicine BresaGen Limited	, igaiso appeal
				School of Medicine BresaGen Limited	· galoor appeal
				School of Medicine BresaGen Limited	, igaios appeal
				School of Medicine BresaGen Limited	, igaios appeal
				School of Medicine BresaGen Limited	, galoo ppeul
				School of Medicine BresaGen Limited	, galoor appeal
				School of Medicine BresaGen Limited	·
				School of Medicine BresaGen Limited	·

*EXAMINER: Initial if references considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. This collection is attached or the patent Documents at www.uspto.gov or MPEP 901.04. This collection is attached ST.35. This is collection is attached ST.36. Patent Documents or the USPTO Documents or the Uspto.gov or MPEP 901.04. This collection is attached ST.36. Thi

U.S. Pate action Act of 1995, no persons are required to respond to a collection

	Under the Pa	perw	tion Act of 1995, a	no persons are required to respond to a col	lection mation unless it contains a valid OMB control number.		
Substitute for for	m 1449/PTO			Complete if Known			
				Application Number 10/529,115			
INFO	RMATION D	ISCLOS	SURE	Filing Date	March 24, 2005		
	TEMENT BY			First Named Inventor	Brian G. Condie		
	Use as many sheets			Art Unit			
	Ose as many sneets	as necessary	"	Examiner Name			
Sheet	2	of	3	Attorney Docket Number	18377-0059		

Sheet		2	of	3	Attorney Docket Number	18377-0059				
				NON PAT	ENT LITERATURE DOCUMEN	TS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.								
		BAIN, et	al., 1995, "Em	ibryonic Stem (Cells Express Neuronal Propertie	es in vitro," Dev. Biology, 168:342-357.				
					of Apoptosis During Neuronal Deal Chemistry, 276:44396-44404	ifferentiation by Ceramide and b-Series Complex				
		BIEBERICH, et al., 1999, "Differential Effects of Glycolipid Biosynthesis Inhibitors on Ceramide-Induced Cell Death in Neuroblastoma Cells," Journal of Neurochemistry, 72:1040-1049.								
		Regions	throughout the	e Central Nervo	ous System," The Journal of Con	ture of Embryonic and Postnatal Neuroproliferative aparative Neurology, 396:39-50.				
		Cerebral	Cortex," Deve	elopment, 122:1	1165-1174.	liferative and Postmitotic Regions of the Fetal				
		BRUGG, et al., 1996, "Ceramide Induces Apoptosis in Cultured Mesencephalic Neurons," <i>Journal of Neurochemistry</i> , 66:733-739.								
		Proc. Na	tl. Acad. Sci. U	JSA , 94:14809	-14814.	pate in Mammalian Brain Development",				
		CARPENTER, et al., 2001, "Enrichment of Neurons and Neural Precursors from Human Embryonic Stem Cells", Exper. Neuro., 172:383-397.								
		its Recep	otor p75," Natu	<i>ir</i> e, 383:716-71	9.	iated by the Interaction of Nerve Growth Factor with				
	ļ	CHUN, Jerold, 2000, "Cell Death, DNA Breaks and Possible Rearrangements: An Alternative View," Trends in Neuroscience, 23:407–408.								
		DECRAENE, et al., 2002, "Identification of Genes Involved in Ceramide-Dependent Neuronal Apoptosis using cDNA Arrays," Genome Biol., 3(8)research 0042.1-0042.22.								
		ESDAR, et al., 2001, "Differentiation-Associated Apoptosis of Neural Stem Cells is Effected by Bcl-2 Overexpression: Impact on Cell Lineage Determination", Eur. J. Cell Biol., 80:539-553.								
		FRAICHARD, et al., 1995, "In Vitro Differentiation of Embryonic Stem Cells into Glial Cells and Functional Neurons", J. Cell Sci. ,108:3181-3188.								
		FURUYA, et al., 1998, "Ceramide and Its Interconvertible Metabolite Sphingosine Function as Indispensable Lipid Factors Involved in Survival and Dendritic Differentiation of Cerebellar Purkinje Cells," <i>Journal of Neurochemistry</i> , 71:366-377.								
		HARTFIELD, et al., 1997, "Ceramide Induces Apoptosis in PC12 cells," FEBS Letters," 401:148-152.								
		Journal o	of Biological Ci	hemistry, 275:3	0344-30354.	uring Early Neural Differentiation in Vitro, The				
		IRIE, et al., 1998, "Application of Exogenous Ceramide to Cultured Rat Spinal Motoneurons Promotes Survival or Death by Regulation of Apoptosis Depending on its Concentrations," <i>Journal of Neuroscience Research</i> , 54:475-485.								
		ITO, et al., 1995, "Ceramide Prevents Neuronal Programmed Cell Death Induced by Nerve Growth Factor Deprivation," Journal of Neurochemistry, 65:463-466.								
		JAFFRÉZOU, et al., 1998, "Positive Feedback Control of Neural Sphingomyelinase Activity by Ceramide," FASEB, 12:999-1006.								
		KAWASAKI, et al., 2002, "Generation of Dopaminergic Neurons and Pigmented Epithelia from Primate ES Cells by Stromal Cell-Derived Inducing Activity", <i>Proc. Natl. Acad. Sci.</i> USA, 99(3):1580-1585.								
		KAWASAKI, et al., 2000, "Induction of Midbrain Dopaminergic Neurons from ES Cells by Stromal Cell-Derived Inducing Activity", Neuron, 28:31-40.								
		KIM, et al., 2002, "Dopamine Neurons Derived from Embryonic Stem Cells Function in an Animal Model of Parkinson's Disease", <i>Nature</i> 418:50-56.								
		LI, et al., 1998, "Generation of Purified Neural Precursors from Embryonic Stem Cells by Lineage Selection", Current Biol. 8:971-974.								
				oxic Precondition ysiol., 278:C14		against Hypoxic stress via TNF-α and Ceramide,"				
xaminer lignature						Date Considered				
'igriatule						Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number (optional). 'Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO					Complete if Known			
					Application Number	10/529,115		
INFORMATION DISCLOSURE				LIRE	Filing Date	March 24, 2005		
STATEMENT BY APPLICANT				First Named Inventor	Brian G. Condie			
				Art Unit				
(Use as many sheets as necessary)					Examiner Name			
Sheet		3	of	3	Attorney Docket Number	18377-0059		
	<u> </u>			NON PATI	ENT LITERATURE DOCUMENT	S		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the articles (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
		OBEID,	et al., 1993, "	Programmed Cell	Death Induced by Ceramide," So	cience, 259:1769-1771.		
		Stem Ce	lls in Vitro", I	Mech. Dev. 59:89-	-102.	nctional Postmitotic Neurons from Embryonic		
					of Embyronic Stem Cells*, Meth.			
					Derived in Vitro from ES Cells E Dev. 79:185-197.	xpress Homeoproteins Characteristic of		
		REUBIN	OFF, et al., 2	2001, "Neural Prog	genitors from Human Embryonic	Stem Cells", Nature Biotech 19(12):1134-1140.		
			DINER, et al., es. 913-201-2		Neuronal Differentiation of Human	n Embryonic Stem Cells",		
		STRUBI	NG, et al., 19	95, "Differentiatio	n of Pluripotent Embryonic Stem y Neurons", Mech. Dev. 53:275-2	Cells into the Neuronal Lineage in Vitro Gives		
		TOMAN,	et al., 2002,	"Ceramide-Induc	ed Cell Death in Primary Neurona f Neuroscience Research, 68:323	al Cultures: Upregulation of Ceramide Levels		
		TROPER	PE, et al., 200	01, "Direct Neural	Fate Specification from Embryon efault Mechanism*, Neuron, 30:65	ic Stem Cells: A Primitive Mammalian Neural		
		ZHANG,	et al., 2001,	"In Vitro Different 2):1129-1133.	iation of Transplantable Neural P	recursors from Human Embryonic Stem Cells",		
							ļ	
	<u> </u>							
		-						
								
						· · · · · · · · · · · · · · · · · · ·		
·								
				· · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·		
				· <u> </u>			$\vdash \vdash \vdash$	
Examiner		L			D	ate	1	

considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Considered

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Signature

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not